News

Zenas BioPharma Shares Positive Q3 Results and Pipeline Updates

Zenas BioPharma Shares Positive Q3 Results and Pipeline Updates

Zenas BioPharma Releases Q3 2025 Financial Results

Zenas BioPharma, Inc. (NASDAQ: ZBIO) has presented its financial results for the third quarter that concluded on September 30, 2025. The company, dedicated to transforming healthcare for patients with autoimmune diseases, has made noteworthy strides in its clinical programs and financial standing.

Significant Achievements in Clinical Trials

Lonnie Moulder, the founder and CEO of Zenas, emphasized the company's commitment to developing impactful treatments. Key highlights include:

  • Phase 3 INDIGO Trial: The results for the obexelimab Phase 3 INDIGO trial focusing on Immunoglobulin G4-Related Disease (IgG4-RD) are anticipated towards the end of 2025.
  • Successful Phase 2 Trial: Zenas reported excellent results from its Phase 2 MoonStone trial evaluating obexelimab in Relapsing Multiple Sclerosis (RMS), showcasing a remarkable reduction in lesions compared to the placebo.
  • Expansion of Pipeline: The company has acquired development rights to three autoimmune product candidates, among them orelabrutinib, currently in Phase 3 for progressive forms of Multiple Sclerosis.
  • Funding Milestones: A funding agreement with Royalty Pharma could provide up to $300 million to help support clinical development and eventual commercial launch plans.

Recent Corporate Highlights

Zenas's corporate activities are geared towards strengthening its position in the biopharmaceutical landscape:

  • Pioneering IgG4-RD Research: The INDIGO trial is among the largest global studies dedicated to IgG4-RD, indicating Zenas's robust commitment towards understanding and treating this condition.
  • Impressive Clinical Efficacy: The MoonStone trial revealed a 95% relative reduction in the cumulative number of gadolinium-enhancing lesions after 12 weeks. This suggests obexelimab could significantly advance RMS treatment.
  • Innovative Licensing Agreements: Collaboration with InnoCare Pharma expands Zenas’s portfolio with orelabrutinib, alongside other promising drug candidates that target critical aspects of multiple sclerosis.
  • Funding for Growth: The $120 million raised from a private placement will bolster Zenas's funding for ongoing research and development initiatives into 2026 and beyond.

Financial Overview

As of September 30, 2025, Zenas BioPharma reported cash and investments totaling $301.6 million. This amount is anticipated to sustain operations and capital requirements through 2026. The company recorded an R&D expense of $34.4 million for the quarter, reflecting its investment in advancing clinical trials, while G&A expenses soared to $13.2 million, primarily due to increased personnel costs and pre-commercialization expenses.

The net loss attributed to the common stockholders for Q3 2025 was $51.5 million, a rise from the $38.6 million recorded during the same period in 2024.

Pipeline Developments

Key updates regarding Zenas's pipeline include:

  • Obexelimab: This candidate is undergoing trials for various autoimmune conditions. The company aims to complete enrollment for its Phase 2 SunStone trial, focusing on Systemic Lupus Erythematosus, by year-end 2025.
  • Orelabrutinib: Preparing to embark on Phase 3 trials for both Primary and Secondary Progressive Multiple Sclerosis, marking a significant step forward in addressing these challenging forms of MS.
  • Innovative Drug Candidates: Zenas is also progressing with ZB021 and ZB022, two advanced candidates that could offer groundbreaking treatment options for autoimmune conditions and neurologic diseases.

About Zenas BioPharma

Founded on the principles of providing transformative therapies to patients with autoimmune diseases, Zenas BioPharma is making considerable advancements in the field of biopharmaceuticals. With a strong leadership team and a disciplined approach to product acquisition, the company is focused on developing innovative therapies with the potential to significantly change patient lives.

Frequently Asked Questions

What recent results did Zenas BioPharma announce?

Zenas BioPharma announced positive financial results for Q3 2025 and significant progress in clinical trials for obexelimab and orelabrutinib.

What is obexelimab used for?

Obexelimab is a monoclonal antibody aimed at treating autoimmune diseases, including Relapsing Multiple Sclerosis and Immunoglobulin G4-Related Disease.

How is the company financially positioned?

Zenas reported $301.6 million in cash and investments, sufficient to fund operations through 2026 and beyond.

What are the next steps for Zenas's drug candidates?

Zenas plans to report Phase 3 trial results for obexelimab by the end of 2025 and is advancing orelabrutinib trials in 2026.

Where can I find more information about Zenas BioPharma?

You can visit Zenas BioPharma’s website for more information about their programs and updates.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Superteam Wheels Rides Into Spain with RACEIT Deal

Updated Category News Views 151

Rolling Out the Red Carpet for Spanish Cyclists Think of it as the pedal-powered bridge from wherever Superteam Wheels calls home to the sunny streets of Spain. If you're in the cycling game, this new partnership between Superteam Wheels and COMERTECH RACEIT, S.L., better known as RACEIT, is drawing a line in the sand—or perhaps on the asphalt—across Europe. Starting...

Continue Reading
Sinopec's Catalyst Conference: Driving Global Innovation

Updated Category News Views 90

The Role of Catalysts in Modern Industry Swing by any bustling industrial hub, and you're likely to catch talk about catalysts—unsung heroes that make the machinery of modern industry run smoother, faster, and cleaner. Over in Tianjin, China, Sinopec just wrapped up its Second International Catalyst Customer Conference, which is less of a tongue-twister than it sounds....

Continue Reading
National Civics Day: LIU Unveils Screen-Free Platform

Updated Category News Views 60

A Tradition Reimagined for a Milestone You ever look at a calendar and feel the weight of history? That's what's happening right now at Long Island University as America hits 250 years in the books. We're not just polishing dusty history statues—on October 27, there's a genuine push to get back to basics. Brian Kilmeade's stepping into the spotlight as he headlines this...

Continue Reading
Teamsters Secure Strong Contract for CA Waste Workers

Updated Category News Views 44

Teamsters Flex Muscles in So-Cal Sanitation Sector So here's one for the books: 700 Waste Management workers represented by Teamsters Local 396 just locked down a fresh collective bargaining agreement in Los Angeles and Orange counties. And let me tell you, this isn’t just another contract—it's a testament to what solidarity can wring out of a massive corporation. The...

Continue Reading
Surgery Partners Buyout: Fair Deal or Insider Jackpot?

Updated Category News Views 66

What's Going On With Surgery Partners? Alright, here's the scoop that shareholders can't ignore—Surgery Partners (NYSE:SGRY) could be heading under the scalpel itself with a proposed buyout by HealthSpan. For those holding onto SGRY stock, this might feel like watching the rerun of a medical drama where the ending ain't clear yet. Shareholders are set to get $23.50 a...

Continue Reading
Exploring Family, Faith, and Forgiveness in New Book

Updated Category News Views 113

Diving into the Depths of Faith and Forgiveness T.L. Dennis ain't just spinning a yarn about his childhood in "A Conversation with a Dead Father". This is a deep dive into the gritty realities of his relationship with his old man, seasoned with the salt of personal struggles and spiritual redemption. The pages of this book open at the one place none of us look for good...

Continue Reading
Bertram Capital Backs MCE's Expansive Growth Vision

Updated Category News Views 92

A Strategic Move for Bertram Capital Right on the heels of seasoned market moves, Bertram Capital has thrown its support behind Motion & Control Enterprises (MCE). This isn't just another portfolio addition; it's a calculated step into the complex world of industrial distribution, partnering with a company renowned for its prowess in engineered solutions. If you've ever...

Continue Reading
United Vein Expands Vero Beach Network for Specialized Care

Updated Category News Views 99

Simplifying Vein Healthcare in Vero Beach Out of all the surprises life throws, leg cramps and bulging veins seem like small potatoes—until they're not. That's why folks in Vero Beach got a new lifeline today with the United Vein & Vascular Centers opening another clinic. At the crossroads of the 37th Street medical district, this place puts specialized vein care right...

Continue Reading
Massive $1B Jobs Initiative Fights AI Automation Impact

Updated Category News Views 73

Initiative Tackles Economic Shifts Head-On AI and automation are turning the job market upside down, and more than 20 foundations and philanthropies are throwing their weight behind a $1 billion initiative called All In For Jobs. Their aim? Connect half a million Americans to stable, decent-paying jobs and prepare communities to face the daunting transition imposed by...

Continue Reading
Gildan's Troubling Legal Struggles: Investor Action Alert

Updated Category News Views 13

Gildan's Bumpy Ride: Legal Woes Unfold Well, folks, seems like Gildan Activewear Inc. (NYSE:GIL) is in for a bumpy ride, and not the kind that makes you feel alive, I tell ya. They've been slapped with a class action lawsuit, and the news ain't pretty. Accusations are flying hot about how they've been playing fast and loose with their financials. The Allegations: Channel...

Continue Reading

Top 5 Most Recently Viewed Articles

Heartland Express Announces 90th Dividend Distribution Milestone

Updated Category News Views 81

Heartland Express Declares Regular Quarterly Dividend The Board of Directors of Heartland Express, Inc. (NASDAQ: HTLD) has made a significant announcement regarding its regular quarterly cash dividend. This dividend, amounting to $0.02 per share, reflects the company’s commitment to returning value to its shareholders. Scheduled for payment on January 7, 2026, the...

Continue Reading
Neuroscience Market Growth Forecast: $50.2 Billion by 2032

Updated Category News Views 112

Neuroscience Market Growth Insights The neuroscience market is witnessing remarkable expansion, reflecting a broader understanding and heightened awareness of neurological health. Current reports suggest that the market size was valued at approximately USD 35.3 billion, with projections indicating it will escalate to USD 50.2 billion by 2032. This growth corresponds to a...

Continue Reading
Impact of Long-Term Investment in Nike on Wealth Growth

Updated Category News Views 298

The Evolution of Nike Investments Over 20 Years Nike (NKE) has demonstrated outstanding financial performance over the last two decades, delivering an annualized return that outstrips the market by 1.56%. This remarkable growth has led to an impressive average annual return of 10.05% for investors. As it stands, Nike boasts a staggering market capitalization of $110.34...

Continue Reading
C2N Innovations Funded to Enhance Alzheimer’s Testing Capabilities

Updated Category News Views 198

C2N Diagnostics Secures Major Funding for Alzheimer’s Testing Innovations C2N Diagnostics, a frontrunner in the diagnostics industry, has successfully obtained crucial funding aimed at transforming Alzheimer’s disease testing. This initiative is focused on empowering local clinical laboratories to provide precise and automated mass spectrometry solutions, ultimately...

Continue Reading
Goldman Sachs Gr: Uncovering the Rising Options Market Trends

Updated Category News Views 311

Goldman Sachs Gr: Analyzing the Surge in Options Activity In recent times, investors have shifted towards a bullish stance regarding Goldman Sachs Gr (NYSE: GS), a trend that demands the attention of market observers. Recent data reveals a significant increase in options activity related to GS, which may indicate potential movements in the stock price. The identities of...

Continue Reading